The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
Lawrence A LeiterStephen D WiviottHiddo J Lambers HeerspinkJamie P DwyerAvivit CahnErica L GoodrichAliza RozenbergMeir SchechterIlan YanuvSabina A MurphyThomas A ZelnikerIngrid A M Gause-NilssonAnna Maria LangkildeMartin FredrikssonPeter A JohanssonDeepak L BhattLawrence A LeiterDarren K McGuireJohn P H WildingMarc S SabatineItamar RazPublished in: Diabetes care (2021)
In DECLARE-TIMI 58, dapagliflozin demonstrated a favorable effect on UACR and renal-specific outcome across baseline UACR categories, including patients with normal albumin excretion. The results suggest a role for SGLT2i also in the primary prevention of diabetic kidney disease.
Keyphrases